Category
Cancer
Sub Category
Lung
Study Name
A081105: Randomized, Double-blind, Placebo COntrolled Study of erlotinib or placebo in Patients with Completely Resected Epidermal Growth factor Receptor (EGFR) mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator
Gordon Srkalovic, MD, PhD
Study Information
Contact for Questions
Sparrow Cancer Center 800-968-5570

Site view: at a glance